Live Quote · OTCKLDOHealthcare· Biotechnology

Kaleido Biosciences, Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
59/100
Mixed
100
Valuation
20
Profitability
80
Growth
64
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLDO research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$0.20
Company Overviewkaleido.com

About the company

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19.

CEO
Mark A. Wingertzahn
IPO
2019
Employees
76
HQ
Lexington, MA, US

Price Chart

+9900.00% · this period
$0.35$0.18$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$4.26K
P/E
-0.00
P/S
0.00
P/B
0.00
EV/EBITDA
0.20
Div Yield
0.00%
Profitability
Gross Margin
-113.59%
Op Margin
-7940.85%
Net Margin
-8178.26%
ROE
-580.57%
ROIC
-239.53%
Growth & Income
Revenue
$1.10M · 13.23%
Net Income
$-90,288,000 · -10.62%
EPS
$-2.16 · 11.48%
Op Income
$-87,667,000
FCF YoY
-19.35%
Performance & Tape
52W High
$0.20
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
-1.17
Avg Volume
1.87K

Get TickerSpark's AI analysis on KLDO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Feb 28, 22van Hylckama Vlieg Johanother2,087
Feb 28, 22Korn Jeraldother2,046
Jan 14, 22van Hylckama Vlieg Johanother350,000
Jan 14, 22Long Alison Sother125,000
Jan 14, 22Long Alison Sother46,800
Jan 14, 22Korn Jeraldother250,000
Jan 14, 22Korn Jeraldother45,240
Jan 14, 22Duke William E.other125,000
Jan 14, 22Duke William E.other44,990
Jan 14, 22Menichella Daniel Lother250,000
Coverage · KLDO

Our KLDO coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on KLDO yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate KLDO report →
Internal Compare

Similar companies

Peers in the same neighborhood.